Psyence Biomedical (PBM) Stock Price, News & Analysis

Company Overview

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Key Stats

• Today's Range: $1.27 to $1.40
• 50-Day Range: $1.23 to $3.18
• 52-Week Range: $1.15 to $323.25
• Volume: 262,826 shs
• Average Volume: 353,924 shs
• Market Capitalization: $8.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PBM Stock Analysis - Frequently Asked Questions

How have PBM shares performed this year?

Psyence Biomedical's stock was trading at $2.11 at the start of the year. Since then, PBM stock has decreased by 38.4% and is now trading at $1.30.
View the best growth stocks for 2025 here.

How were Psyence Biomedical's earnings last quarter?

Psyence Biomedical Ltd. (NASDAQ:PBM) issued its quarterly earnings data on Thursday, January, 23rd. The company reported $0.51 EPS for the quarter.

When did Psyence Biomedical's stock split?

Psyence Biomedical's stock reverse split on Tuesday, November 26th 2024. The 1-75 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Who are Psyence Biomedical's major shareholders?

Psyence Biomedical's top institutional shareholders include Harraden Circle Investments LLC (2.76%), Essential Planning LLC. (1.11%), AdvisorShares Investments LLC (0.41%) and Virtu Financial LLC (0.19%).

How do I buy shares of Psyence Biomedical?

Shares of PBM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Psyence Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Psyence Biomedical investors own include BlackRock ESG Capital Allocation Term Trust (ECAT), Barings Global Short Duration High Yield Fund (BGH), BlackRock Innovation and Growth Term Trust (BIGZ), BlackRock Health Sciences Term Trust (BMEZ), Saba Capital Income & Opportunities Fund (BRW), BlackRock Science and Technology Term Trust (BSTZ) and Cameco (CCJ).

Company Calendar

• Last Earnings: 1/23/2025
• Today: 2/22/2025
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PBM
• Previous Symbol: NASDAQ:PBM
• CUSIP: N/A
• CIK: 1985062
• Web: www.psyencebiomed.com
• Phone: 510-214-3750
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.64
• Quick Ratio: 0.64

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($61.61) per share
• Price / Book: -0.02

Miscellaneous

• Outstanding Shares: 6,600,000
• Free Float: 6,364,000
• Market Cap: $8.58 million
• Optionable: N/A
• Beta: -0.48